Featured Publications
Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes
Sundar R, Chia D, Zhao J, Lee A, Kim G, Tan H, Pang A, Shabbir A, Willaert W, Ma H, Huang K, Hagihara T, Tan A, Ong C, Wong J, Seo C, Walsh R, Chan G, Cheo S, Soh C, Callebout E, Geboes K, Ng M, Lum J, Leow W, Selvarajan S, Hoorens A, Ang W, Pang H, Tan P, Yong W, Chia C, Ceelen W, So J. Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes. ESMO Open 2024, 9: 103681. PMID: 39288528, PMCID: PMC11421236, DOI: 10.1016/j.esmoop.2024.103681.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedNivolumabOxaliplatinPeritoneal NeoplasmsStomach NeoplasmsTreatment OutcomeConceptsGastric cancer peritoneal metastasisPeritoneal cancer indexNivolumab combinationPeritoneal metastasisPeritoneal tumorsNaive CD8+ T cellsCD8+ central memoryEnhanced T cell infiltrationTreatment-related adverse eventsCD8+ T cellsGrade 4 vomitingRegression grade 1First-in-human trialImmune checkpoint inhibitionMemory CD4+T cell infiltrationImmunogenic cell deathSystemic immunotherapyCheckpoint inhibitionSystemic therapyCancer indexCD4+Intraperitoneal treatmentT cellsAdverse eventsMachine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial
Sundar R, Kumarakulasinghe N, Chan Y, Yoshida K, Yoshikawa T, Miyagi Y, Rino Y, Masuda M, Guan J, Sakamoto J, Tanaka S, Tan A, Hoppe M, Jeyasekharan A, Ng C, De Simone M, Grabsch H, Lee J, Oshima T, Tsuburaya A, Tan P. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut 2021, 71: 676-685. PMID: 33980610, PMCID: PMC8921574, DOI: 10.1136/gutjnl-2021-324060.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalHumansMachine LearningPaclitaxelStomach NeoplasmsConceptsDisease free survivalValidation cohortGastric cancerGene signatureSurvival benefitPac-SensitiveNo survival differenceSelection of patientsGC trialsFree survivalPaclitaxel chemotherapyCurative surgeryMetastatic patientsPredictive biomarkersTraining cohortSurvival differencesIndependent cohortNanoString panelGC patientsPaclitaxelPatientsNanoString profilingCohortGroup trialUFTAre we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy
Molassiotis A, Cheng H, Lopez V, Au J, Chan A, Bandla A, Leung K, Li Y, Wong K, Suen L, Chan C, Yorke J, Farrell C, Sundar R. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 2019, 19: 132. PMID: 30736741, PMCID: PMC6368751, DOI: 10.1186/s12885-019-5302-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesDose-Response Relationship, DrugFemaleHumansLongitudinal StudiesMaleMiddle AgedNeoplasm StagingNeoplasmsPatient Reported Outcome MeasuresPeripheral Nervous System DiseasesPrevalenceProspective StudiesQuality of LifeSeverity of Illness IndexConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyNeurotoxic chemotherapyPrevalence of sensory neuropathyCohort study of patientsCumulative chemotherapy dosePlatinum-based chemotherapyLongitudinal cohort study of patientsMeasuring chemotherapy-induced peripheral neuropathyStudy of patientsNerve conduction studiesAssessment of chemotherapy-induced peripheral neuropathyCIPN incidencePatient-reported outcome measuresAssociated with onsetLongitudinal cohort studyChemotherapy doseMotor neurotoxicityClinician-based scalesMotor neuropathySensory neuropathyChemotherapyNeuropathyNatural historyPatients
2024
Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review
Shitara K, Falcone A, Fakih M, George B, Sundar R, Ranjan S, Van Cutsem E. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review. The Oncologist 2024, 29: e601-e615. PMID: 38366864, PMCID: PMC11067808, DOI: 10.1093/oncolo/oyae007.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsDrug CombinationsHumansPyrrolidinesThymineTrifluridineConceptsMetastatic colorectal cancerRefractory metastatic colorectal cancerAdverse eventsDiscontinuation rate due to adverse eventsColorectal cancerChemorefractory metastatic colorectal cancerSafety outcomesMedian overall survivalSafety of FTD/TPIProgression-free survivalAdvanced solid tumorsAssociated with improved outcomesEarly-phase studiesSystematic reviewOverall survivalFTD/TPIRetrospective studySolid tumorsBevacizumabClinical efficacyTargeted agentsTumor typesAntineoplastic agentsAdvanced cancerImprove outcomes
2023
Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer
Smyth E, Sundar R. Combining chemotherapy, trastuzumab, and immune-checkpoint inhibitors in HER2-positive gastro-oesophageal cancer. The Lancet 2023, 402: 2168-2170. PMID: 37871605, DOI: 10.1016/s0140-6736(23)02296-1.Commentaries, Editorials and LettersMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsHumansImmune Checkpoint InhibitorsReceptor, ErbB-2Stomach NeoplasmsTrastuzumabEvidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma—Reply
Zhao J, Pietrantonio F, Sundar R. Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma—Reply. JAMA Oncology 2023, 9: 1005-1006. PMID: 37166787, DOI: 10.1001/jamaoncol.2023.0975.Commentaries, Editorials and LettersMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaHumansImmune Checkpoint InhibitorsEffects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS)
Shitara K, George B, Taieb J, Sundar R, Fakih M, Makris L, Benhadji K, Ghidini M. Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS). Journal Of Cancer Research And Clinical Oncology 2023, 149: 9361-9374. PMID: 37213030, PMCID: PMC10374776, DOI: 10.1007/s00432-023-04813-z.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsDrug CombinationsEsophagogastric JunctionHumansIrinotecanPaclitaxelPyrrolidinesStomach NeoplasmsTrifluridineConceptsProgression-free survivalGastric/gastroesophageal junction cancerJunction cancerSurvival benefitSafety profileEastern Cooperative Oncology Group performance statusRandomized phase III trialAssociated with survival benefitMedian overall survivalPhase III trialsPost hoc exploratory analysisLater-lineTrifluridine/tipiracil treatmentHematologic toxicityPrior therapyMedian overallOverall survivalIII trialsPlacebo armPerformance statusResultsBaseline characteristicsMedian timeRamucirumabTherapy patternsClinical trialsControversies in upper GI oncology: first-line checkpoint inhibitor use in metastatic GEA: guided by PD-L1 CPS or not?
Petrillo A, Maron S, Sundar R. Controversies in upper GI oncology: first-line checkpoint inhibitor use in metastatic GEA: guided by PD-L1 CPS or not? ESMO Open 2023, 8: 101211. PMID: 37054477, PMCID: PMC10123152, DOI: 10.1016/j.esmoop.2023.101211.Commentaries, Editorials and LettersMeSH KeywordsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenHumans
2022
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases
Chia D, Sundar R, Kim G, Ang J, Shabbir A, So J, Yong W. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2022, 30: 1889-1890. PMID: 36564654, DOI: 10.1245/s10434-022-12877-3.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCapecitabineFluorouracilHumansOxaliplatinPeritoneal NeoplasmsStomach NeoplasmsOutcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases
Chia D, Sundar R, Kim G, Ang J, Lum J, Nga M, Goh G, Seet J, Chee C, Tan H, Ho J, Ngoi N, Lee M, Muthu V, Chan G, Pang A, Ang Y, Choo J, Lim J, Teh J, Lwin A, Soon Y, Shabbir A, So J, Yong W. Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases. Annals Of Surgical Oncology 2022, 29: 8597-8605. PMID: 36070113, DOI: 10.1245/s10434-022-11998-z.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsCapecitabineDeoxycytidineFluorouracilHumansOxaliplatinPaclitaxelPeritoneal NeoplasmsPlatinumStomach NeoplasmsConceptsGastric cancer peritoneal metastasisIP-PTXConversion surgeryIntraperitoneal paclitaxelMedian OSSystemic chemotherapyPeritoneal metastasisSC groupConversion to negative cytologyResultsThe median OSProgression-free survivalPhase II studyMethodsForty-four patientsIntravenous oxaliplatinMedian PFSOral capecitabineSystemic capecitabineExtraperitoneal metastasesNegative cytologyPeritoneal diseaseOverall survivalPerformance statusPrimary endpointSecondary endpointsIP cohortPhase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer.
Lim J, Wong A, Ow S, Ngoi N, Chan G, Ang Y, Chong W, Lim S, Lim Y, Lee M, Choo J, Tan H, Yong W, Soo R, Tan D, Chee C, Sundar R, Yadav K, Jain S, Wang L, Tai B, Goh B, Lee S. Phase Ib/II Dose Expansion Study of Lenvatinib Combined with Letrozole in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer. Clinical Cancer Research 2022, 28: 2248-2256. PMID: 35363275, DOI: 10.1158/1078-0432.ccr-21-4179.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsFemaleHumansLetrozolePhenylurea CompoundsPostmenopauseQuinolinesReceptor, ErbB-2Receptors, EstrogenConceptsBreast cancerDose expansionEstrogen receptorHormone receptor-positive breast cancerPhase II dose expansionRecommended phase II doseReceptor-positive breast cancerCDK4/6 inhibitor therapyDose-expansion studyPaired tumor biopsiesPhase Ib/II trialPhase II doseVascular normalization indexTreated with lenvatinibDose of lenvatinibER+/HER2- breast cancerMetastatic breast cancerPreliminary antitumor activityEstrogen-responsive genesLenvatinib combinationII doseMetastatic settingInhibitor therapyMultikinase inhibitorTumor biopsiesPhase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
Lee M, Wong A, Ow S, Sundar R, Tan D, Soo R, Chee C, Lim J, Yong W, Lim S, Goh B, Wang L, Lee S. Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors. Targeted Oncology 2022, 17: 141-151. PMID: 35195837, PMCID: PMC8995271, DOI: 10.1007/s11523-022-00867-0.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarboplatinFemaleHumansPaclitaxelProtein Kinase InhibitorsTrastuzumabTreatment OutcomeConceptsHER2+ metastatic breast cancerDose-limiting toxicityMetastatic breast cancerBreast cancerSubcutaneous trastuzumabSolid tumorsConclusionsThe recommended phase II dosePharmacokinetic analysisRecommended phase II doseHER2+ breast cancerAdvanced solid tumorsPalliative systemic therapyMetastatic solid tumorsResultsThirty-seven patientsArea under the curveWeekly paclitaxelNeoadjuvant therapyStable diseaseFebrile neutropeniaPartial responseSystemic therapyMethodsEligible patientsEfficacy signalsElectrolyte disturbancesBiliary tract
2021
“3G” Trial: An RNA Editing Signature to Guide Gastric Cancer ChemotherapyRNA Editing Signature in Gastric Cancer
An O, Song Y, Ke X, So J, Sundar R, Yang H, Rha S, Lee M, Tay S, Ong X, Tan A, Ng M, Tantoso E, Chen L, Tan P, Yong W, Consortium S. “3G” Trial: An RNA Editing Signature to Guide Gastric Cancer ChemotherapyRNA Editing Signature in Gastric Cancer. Cancer Research 2021, 81: 2788-2798. PMID: 33558338, DOI: 10.1158/0008-5472.can-20-2872.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorClinical Trials as TopicCohort StudiesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansNeoplasm Recurrence, LocalPrognosisRNA EditingStomach NeoplasmsSurvival RateConceptsAdvanced gastric cancerRNA editingRNA editing signaturesEditing levelsGastric cancerRNA editing eventsHigher editing levelsAdenosine-to-inosineRNA editing analysisGastric cancer cell linesPredictive biomarkersStratify patientsLevels of editingGene expression profilesPredicting response to chemotherapyEditing sitesEditing eventsMolecular subtypes of gastric cancerCancer cell linesPlatinum-based chemotherapyMetastatic gastric cancerSubtypes of gastric cancerCancer Genome AtlasFirst-line therapyResponse to chemotherapy
2020
Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease
Collins D, Sundar R, Constantinidou A, Dolling D, Yap T, Popat S, O’Brien M, Banerji U, de Bono J, Lopez J, Tunariu N, Minchom A. Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. BMC Cancer 2020, 20: 1210. PMID: 33298007, PMCID: PMC7724793, DOI: 10.1186/s12885-020-07662-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsBrain NeoplasmsClinical Trials, Phase I as TopicCombined Modality TherapyDiagnostic ImagingFemaleHumansKaplan-Meier EstimateLiver NeoplasmsLung NeoplasmsMaleMesothelioma, MalignantMiddle AgedPeritoneal NeoplasmsPleural NeoplasmsProportional Hazards ModelsRetrospective StudiesConceptsDistant metastasisPeritoneal metastasisMPM patientsTreatment paradigmCohort of MPM patientsFrequency of distant metastasesIncidence of bone metastasesPresence of distant metastasesPattern of metastatic spreadDistant metastatic diseaseDistant metastatic disseminationBackgroundMalignant pleural mesotheliomaPresence of symptomsIncidence of boneMetastatic diseaseMetastatic sitesBone metastasesOverall survivalMetastatic spreadContralateral lungPrognostic implicationsMetastatic disseminationRadiological investigationsRetrospective studyPleural mesotheliomaA randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours
Ang Y, Ho G, Soo R, Sundar R, Tan S, Yong W, Ow S, Lim J, Chong W, Soe P, Tai B, Wang L, Goh B, Lee S. A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours. BMC Cancer 2020, 20: 1118. PMID: 33203399, PMCID: PMC7672922, DOI: 10.1186/s12885-020-07616-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCase-Control StudiesDocetaxelFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasmsPrognosisSunitinibSurvival RateConceptsProgression-free-survivalAdvanced solid tumorsBreast cancer patientsSolid tumorsCancer patientsMedian progression-free-survivalRandomized phase II trialMetastatic breast cancer patientsClinical-benefit rateProphylactic G-CSFNon-haematological toxicityPrimary tumor siteAdministration of sunitinibPhase II trialAdvanced solid cancersMedian OSHaematological toxicityDoxorubicin-cyclophosphamideTrial registrationThe studyII trialNeutrophil nadirPrimary endpointSecondary endpointsG-CSFIntermittent administrationIntegration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma
Chong W, Lim C, Sinha A, Tan C, Chan G, Huang Y, Kumarakulasinghe N, Sundar R, Jeyasekharan A, Loh W, Tay J, Yadav K, Wang L, Wong A, Kong L, Soo R, Lau J, Soon Y, Goh R, Ho F, Chong S, Lee S, Loh K, Tai B, Lim Y, Goh B. Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma. Clinical Cancer Research 2020, 26: 5320-5328. PMID: 32816944, DOI: 10.1158/1078-0432.ccr-20-1727.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinDeoxycytidineDisease-Free SurvivalFemaleFluorouracilGemcitabineHumansMaleMiddle AgedNasopharyngeal CarcinomaNeoplasm Recurrence, LocalNeovascularization, PathologicSunitinibConceptsLocally advanced nasopharyngeal carcinomaAdvanced nasopharyngeal carcinomaNasopharyngeal carcinomaConcurrent chemoradiationGemcitabine chemotherapyArm CIncreased immune cell infiltrationComplete metabolic responsePosttreatment tumor biopsiesAnti-VEGF therapyArm A patientsRelapse-free survivalMetastatic nasopharyngeal carcinomaImmune cell infiltrationImmune cell traffickingVEGF axisTumor responseInduction cisplatinAntiangiogenic therapyTumor biopsiesTumor perfusionA patientsFDG-PETPericyte coverageStandard treatment
2019
Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time
Wang M, Cheng H, Lopez V, Sundar R, Yorke J, Molassiotis A. Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time. BMC Cancer 2019, 19: 1151. PMID: 31775665, PMCID: PMC6882224, DOI: 10.1186/s12885-019-6352-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCluster AnalysisFemaleHumansLongitudinal StudiesMaleMiddle AgedNeoplasm StagingNeoplasmsPatient Reported Outcome MeasuresPeripheral Nervous System DiseasesPublic Health SurveillanceQuality of LifeSurveys and QuestionnairesSymptom AssessmentConceptsSymptom clustersCancer Quality of Life Questionnaire CoreTreatment of Cancer Quality of Life Questionnaire CoreQuality of Life Questionnaire CoreImprove symptom managementPatient-reported outcome dataBackgroundChemotherapy-induced peripheral neuropathySymptom management strategiesMethodsA secondary analysisSymptom cluster analysisNeurotoxic chemotherapy agentsEuropean Organization for the ResearchSymptom managementChemotherapy-induced peripheral neuropathySecondary analysisResultsSample sizeCancer diagnosisAssessment pointsPeripheral neuropathyOutcome dataCIPNClinical practiceThe ResearchFollow-upSecondary symptomsDNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial
Sundar R, Ng A, Zouridis H, Padmanabhan N, Sheng T, Zhang S, Lee M, Ooi W, Qamra A, Inam I, Hewitt L, So J, Koh V, Nankivell M, Langley R, Allum W, Cunningham D, Rozen S, Yong W, Grabsch H, Tan P. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. European Journal Of Cancer 2019, 123: 48-57. PMID: 31655359, DOI: 10.1016/j.ejca.2019.09.016.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCisplatinDNA MethylationEpigenesis, GeneticEsophageal NeoplasmsFemaleFluorouracilHumansMaleMiddle AgedNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingPrognosisProportional Hazards ModelsRandomized Controlled Trials as TopicSurvival RateConceptsCS armNeoadjuvant chemotherapyOverall survivalOesophageal adenocarcinomaDNA methylation signaturesHistological subtypes of oesophageal cancerOesophageal cancerIndependent cohortPredictive of chemotherapy benefitSubtypes of oesophageal cancerIndependent cohort of patientsS armCox proportional hazards analysisResectable oesophageal cancerCohort of patientsPredictive of benefitMethylation signaturesDNA methylationPredictive of survivalProportional hazards analysisChemotherapy benefitHistological subtypesMetagene signatureRandomised patientsDNA methylation statusMinimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy
Yeo F, Ng C, Loh K, Molassiotis A, Cheng H, Au J, Leung K, Li Y, Wong K, Suen L, Chan C, Yorke J, Farrell C, Bandla A, Ang E, Lopez V, Sundar R, Chan A. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy. Supportive Care In Cancer 2019, 27: 4753-4762. PMID: 30972646, DOI: 10.1007/s00520-019-04771-8.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedMinimal Clinically Important DifferenceNeoplasmsNeurotoxicity SyndromesOrganoplatinum CompoundsPeripheral Nervous System DiseasesQuality of LifeSurveys and QuestionnairesTaxoidsConceptsMinimal clinically important differenceEORTC QLQ-CIPN20QLQ-CIPN20Clinically important differenceDistribution-based approachMotor subscaleNtx subscaleConclusionThe MCIDChange scoresSensory subscaleFunctional Assessment of Cancer Therapy/Gynecologic Oncology Group-NeurotoxicityImportant differenceStandard error of measurementFACT/GOG-NtxNeurotoxic chemotherapyExperience of symptomsAnchor-based approachError of measurementEuropean Organisation of ResearchDistribution-based methodsPeripheral neuropathyChemotherapy-induced peripheral neuropathyMethodsCancer patientsCycles of chemotherapyWorsening peripheral neuropathy
2018
Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial
Yong W, Rha S, Tan I, Choo S, Syn N, Koh V, Tan S, Asuncion B, Sundar R, So J, Shabbir A, Tan C, Kim H, Jung M, Chung H, Ng M, Tai D, Lee M, Wu J, Yeoh K, Tan P, Consortium O. Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial. Clinical Cancer Research 2018, 24: 5272-5281. PMID: 30045931, DOI: 10.1158/1078-0432.ccr-18-0193.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleGene Expression ProfilingHumansMaleMicroarray AnalysisMiddle AgedNeoplasm GradingNeoplasm StagingStomach NeoplasmsTranscriptomeTreatment OutcomeConceptsGenomic classifierManagement of advanced gastric cancerGastric cancerS-1 regimenOpen-label phaseAdvanced gastric cancerGastric cancer chemotherapySensitivity to oxaliplatinTreated with cisplatinTumor gene expressionMedian turnaround timeTreated with SPGene expression signaturesSOX chemotherapyPatient tumorsTreatment stratificationStratify patientsMetabolic signaturesChemotherapyGene expression profilesOxaliplatinPatientsCancer chemotherapyPredictive valueResponse rate